Vonoprazan-Induced Hypomagnesemia Case Reports and Literature Review

Aiba M and Tsutsumi Y

Published on: 2022-02-26

Abstract

Proton pomp inhibitors (PPIs) are widely used in daily practice to improve symptoms associated with gastric acid secretion and to eradicate H. pylori. Hypomagnesemia is one of the side effects of PPIs and has been widely recognized as a complication of PPIs since the first case was reported in 2006. Vonoprazan is a drug with strong antacid action by a mechanism different from PPIs, and was introduced in Japan in 2015. There have been few reports of adverse events associated with vonoprazan, but considering the mechanism of action, adverse events similar to those associated with PPIs may occur. Although the number of cases of hypomagnesemia caused by vonoprazan is still small, it is possible that the number of similar cases will increase with the widespread use of vonoprazan. In this paper, we review 2 cases of vonoprazan-induced hypomagnesemia and discuss the mechanism about hypomagnesemia associated with antacids.